Brivanib中文名
WebMar 20, 2024 · Liu et al. identify brivanib as a cGAS activity-enhancing compound and provide a proof-of-concept for sensitizing platinum-based chemotherapy by boosting cGAS-mediated antitumor immunity. Brivanib may serve as a drug candidate for sensitizing platinum-based chemotherapeutics in cancer treatment and intervention of cGAS-related … Web之前也有这个疑问，刚谷歌了一下，看到这篇文章： The Names of Targeted Therapies Give Clues to How They Work. 简单说，单克隆抗体药物名字一般以-mab结尾， …
Brivanib中文名
Did you know?
Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma), the most common type of liver cancer. Brivanib is no longer in active development. WebBackground: This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors. Patients and methods: Ninety patients enrolled in this two-part, phase I open-label study of oral brivanib alaninate. The primary objectives of this study were (in part A) dose-limiting …
WebApr 1, 2009 · Brivanib alaninate is converted in vivo to the active compound 19 and demonstrates excellent pharmaceutical properties and significant antitumor activity against L2987 human lung carcinoma ...
WebAug 26, 2013 · Purpose Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors implicated in tumorigenesis and angiogenesis in hepatocellular carcinoma (HCC). An unmet medical need persists for patients with HCC whose tumors do not respond to sorafenib or who cannot tolerate it. This multicenter, … WebAbstract. Purpose: Brivanib alaninate is a prodrug of brivanib (BMS-540215), a potent oral VEGFR-2 inhibitor and is currently in development for the treatment of hepatocellular and …
WebJan 10, 2024 · 中文名. 1- [ [4- [ (4-氟-2-甲基-1H-吲哚-5-基)氧基]-5-甲基吡咯并 [2,1-f] [1,2,4]三嗪-6-基]氧基]-2-丙醇. 英文名. (2R)-1- [4- (4-Fluoro-2-methyl-1H-indol-5-yloxy) …
WebSep 30, 2008 · Brivanib may prevent the tumor mass from expanding by cutting off the supply of nutrients and growth factors to the tumor cells. In addition, the percentage of cells stained with cleaved caspase-3 was significantly increased in brivanib-treated tumors compared with control, suggesting that brivanib caused apoptosis of HCC cells. ... enterprise brand promotion and publicityWebBrivanib 布立尼布 (BMS-540215) Brivanib 布立尼布. 药物类型： 酪氨酸激酶抑制剂. 适应症： 肝癌. 靶点： VEGFR. 是否上市： 临床中. 研发公司： Bristol-My-ers Squibb. 说明 … enterprise bridgeport road richmondWebDec 3, 2010 · The primary objective of this clinical trial is to determine the efficacy of brivanib in the treatment of metastatic renal cell carcinoma in terms of progression-free survival (PFS) in patients who have progressed on treatment with sunitinib, sorafenib, bevacizumab, or pazopanib. The primary endpoint of the trial will be PFS at 16 weeks. dr green medina orthopedicWebBrivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against … enterprise business architect jobsWebBrivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM. dr greenly michiganWebJul 4, 2024 · Brivanib is an oral selective dual receptor tyrosine kinase (RTK) inhibitor of FGFRs and VEGFRs, especially VEGFR2 and FGFR1. In this study, brivanib inhibited … dr green oncologyWebFeb 9, 2010 · Both brivanib and its ester prodrug brivanib alaninate showed potent antitumor activity against L2987 human lung carcinoma xenografts over a variety of doses (Fig. 1C and D). The inhibition of tumor growth relative to control as measured by the treated/control ratio following 9 days of brivanib treatment was 0.85, 0.40, and 0.36 at … dr green obgyn coral springs